Abstract
Executive Summary
This report aims to analyze the current and future potential of cancer
vaccines by examining key fundamentals across the entire pipeline of cancer
vaccine drug candidates. BioSeeker has identified three fundamental dimensions
to outline the competitive landscape within the pharmaceutical industry;
compound type, therapy area and target type. For the purposes of this report,
BioSeeker is focusing on therapeutic cancer vaccines and as such the
commercialized and pipeline prophylactic agents have not been included.
This report is written for you to identify your competition and understand
which targeting strategies are at work within cancer vaccine drug development.
It allows you to pin-point which competitors drugs' clinical out-come may have
bearing on your own drug development and who are developing sequels to
blockbuster drugs. This report also helps you to locate white-spots in the
competitive landscape, giving you little or no competition. Conversly it may
reveal unexpected competition for you.
Drug targets are the critical link between drugs and their role in the
treatment of medical disorders. BioSeeker has surveyed cancer vaccines and
identified 75 drug targets belonging to 109 drugs. This report, Cancer
Vaccine: Aim and Shoot, is an open landscape of resources to build, fuel, and
drive your scientific competitive vehicle for the advancement of cancer
vaccine drugs.
In the report, BioSeeker reports on 66 unique drug target combinations, each
comprised of a different collection or mix of individually defined targets,
for 109 cancer vaccine drugs designed for the treatment of 37 different cancer
indications. The highest degree of distinctiveness among cancer vaccine drugs
is achieved by sorting each of them according to targeted cancer indication,
drug target mix, and drug compound type. At the same time we are also
identifying peer groups of drugs, that is, drugs we consider suitable for
head-to-head comparison during drug development.
To fuel the scientific and competitive thinking, BioSeeker opens the gate into
the presence and relevance of protein-protein interactions between identified
targets of cancer vaccine drugs. No less than 64 protein-protein interactions
were recognized among and between 41 of the 75 included cancer vaccine drug
targets.
Why You Should Own Your Own Copy of this Report:
- 180+ pages, with almost a hundred different tables and figures. Includes
more than 1,000 active links to related resources on the Internet
- A 109 cancer vaccine drugs analysis, under development by 76
investigators, covering more than 236 developmental projects in cancer
- 75 unique, in-depth, drug target profiles, highlighting twelve themes
about the drug target, i.e. protein-protein interaction with other drug
targets, pursued cancer indications, drugs under development, compound types,
presence in the Cancer Genome Project etc.
- A unique drug target combination breakdown of cancer vaccines into tumor
type, compound type, and developmental stage
- Unique drug-protein target and protein-protein of drug targets interactome
analysis
- Pathway profiling of cancer vaccine drug targets
- Pin-point which competitor drugs' clinical out-come may have bearing on
your own drug development
- Who are working on sequels to blockbuster drugs?
- Locate white-spots in the competitive landscape, giving you little or no
competition
In all, this report is a serious reference for any professional interested in
the development of oncology drug targets and the selection/validation of
targeting strategies.
Pages: 184
View Cart
